What is the 13F Pro Quality Score for ATYR?

13F Pro ranks aTYR PHARMA INC (ATYR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ATYR's current score at https://13fpro.ai/company/ATYR (free sign-up required for the full ranking).

Where does 13F Pro source ATYR data?

All aTYR PHARMA INC fundamentals and ownership data come directly from SEC EDGAR. aTYR PHARMA INC files with the SEC under CIK 1339970. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ATYR in?

aTYR PHARMA INC (ATYR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ATYR research updated on 13F Pro?

ATYR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

aTYR PHARMA INC(ATYR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1339970 ATYR stock profile & AI dashboard →

13F Pro Quality Score

8.2/100

Rank #2,931 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ATYR Scores 8/100

exact factor attribution · 2026-09-11

ATYR's composite is driven by earnings growth, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-2.4 pts

3th pct

Shareholder dilution

-2.5 pts

1th pct

Earnings quality

-3.1 pts

19th pct

Capital efficiency

-4.4 pts

6th pct

Scale

-7.4 pts

1th pct

Profitability

-7.4 pts

1th pct

Free cash flow

-7.4 pts

1th pct

Revenue growth

-9.6 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ATYR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for aTYR PHARMA INC (ATYR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATYR at 8.2/100 on a 32-signal composite quality model, placing it at rank #2,931 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), aTYR PHARMA INC reports net income of $-10.3M, free cash flow of $-9.4M. Top institutional holders of ATYR by reported 13-F value include FEDERATED HERMES, VANGUARD CAPITAL MANAGEMENT, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. ATYR trades on the Nasdaq exchange and files with the SEC under CIK 1339970. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATYR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for aTYR PHARMA INC directly from SEC EDGAR. aTYR PHARMA INC's 13F Pro composite quality score has ranged between 6 and 8 since 2026, currently 8.2 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-10.3M

Free Cash Flow

Q2 2026

$-9.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-19.1% YoY

$190.0KFY 2025

FY22 $10.4MFY23 $353.0KFY24 $235.0KFY25 $190.0K

Net Income

-15.8% YoY

$-74.1MFY 2025

FY22 $-45.3MFY23 $-50.4MFY24 $-64.0MFY25 $-74.1M

Operating Income

-14.3% YoY

$-77.6MFY 2025

FY22 $-46.4MFY23 $-54.9MFY24 $-67.9MFY25 $-77.6M

EPS (Diluted)

+7.0% YoY

$-0.80FY 2025

FY22 $-1.60FY23 $-0.94FY24 $-0.86FY25 $-0.80

Total Assets

-4.0% YoY

$93.0MFY 2025

FY22 $95.8MFY23 $120.7MFY24 $96.8MFY25 $93.0M

Op. Cash Flow

+10.3% YoY

$-62.0MFY 2025

FY22 $-41.9MFY23 $-33.2MFY24 $-69.1MFY25 $-62.0M

Free Cash Flow

+10.3% YoY

$-62.1MFY 2025

FY22 $-43.5MFY23 $-37.4MFY24 $-69.2MFY25 $-62.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$190.0K -19.1%	$235.0K -33.4%	$353.0K -96.6%	$10.4M	$0.00 -100.0%	$10.5M
Net Income	$-74.1M -15.8%	$-64.0M -27.1%	$-50.4M -11.1%	$-45.3M -34.3%	$-33.8M -108.1%	$-16.2M
Operating Income	$-77.6M -14.3%	$-67.9M -23.7%	$-54.9M -18.3%	$-46.4M -36.4%	$-34.0M -113.8%	$-15.9M
EPS (Diluted)	$-0.80 +7.0%	$-0.86 +8.5%	$-0.94 +41.3%	$-1.60 +9.6%	$-1.77 +0.0%	$-1.77
Total Assets	$93.0M -4.0%	$96.8M -19.7%	$120.7M +26.0%	$95.8M -17.1%	$115.5M +198.3%	$38.7M
Operating Cash Flow	$-62.0M +10.3%	$-69.1M -108.1%	$-33.2M +20.7%	$-41.9M -26.6%	$-33.1M -116.2%	$-15.3M
Free Cash Flow	$-62.1M +10.3%	$-69.2M -84.8%	$-37.4M +14.0%	$-43.5M -30.8%	$-33.3M -114.6%	$-15.5M

Get alerted when ATYR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for aTYR PHARMA INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ATYR

FEDERATED HERMES, INC.
$5.1M8,509,678 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.3M3,808,091 sh
GSA CAPITAL PARTNERS LLP
$2.1M3,454,863 sh
AQR CAPITAL MANAGEMENT LLC
$1.6M2,610,548 sh
FMR LLC
$1.5M2,471,418 sh
BlackRock, Inc.
$1.1M1,827,332 sh
Kalehua Capital Management LLC
$1.1M1,788,167 sh
JANE STREET GROUP, LLC
$1.0M1,721,297 sh
UBS Group AG
$914.1K1,531,151 sh
MORGAN STANLEY
$801.9K1,343,636 sh

Fund	Value	Shares
FEDERATED HERMES, INC.	$5.1M	8,509,678
VANGUARD CAPITAL MANAGEMENT LLC	$2.3M	3,808,091
GSA CAPITAL PARTNERS LLP	$2.1M	3,454,863
AQR CAPITAL MANAGEMENT LLC	$1.6M	2,610,548
FMR LLC	$1.5M	2,471,418
BlackRock, Inc.	$1.1M	1,827,332
Kalehua Capital Management LLC	$1.1M	1,788,167
JANE STREET GROUP, LLC	$1.0M	1,721,297
UBS Group AG	$914.1K	1,531,151
MORGAN STANLEY	$801.9K	1,343,636

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ATYR on your watchlist

Track score changes the day aTYR PHARMA INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ATYR a good stock to buy?

13F Pro's AI-powered analysis of aTYR PHARMA INC (ATYR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATYR are available on the ATYR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ATYR is classified as a small company.

Which hedge funds own ATYR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATYR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of aTYR PHARMA INC's investment landscape.